Autologous intrauterine platelet-rich plasma instillation for suboptimal endometrium in frozen embryo transfer cycles: A pilot study

Tandulwadkar, Sunita; Naralkar, Manasi; Surana, Akash D; Selvakarthick, M; Kharat, Avinash

doi:10.4103/jhrs.jhrs_28_17

Cited by 74 publications

(71 citation statements)

References 14 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HRT allows for artificial stimulation of endometrial growth via hormone administration orally, transdermally, intramuscularly, vaginally, subcutaneously, or a combination of both. Most clinics administer estradiol for several days until the endometrial lining has reach a point of optimal growth, at which time they will then administer progesterone to induce the secretory phase of cycle that promotes embryo implantation [21]. Each of the studies examined in this review conducted HRT protocols concordant with physician recommendation as follows:…”

Section: Methodsmentioning

confidence: 99%

“…Tandulwadkar et al: Estradiol Valerate started at 6-8 mg/d concordant with baseline endometrial vascularity as measured by Power Doppler on day 1 of menses and increased to 12 mg/d if growth was not seen. Transvaginal ultrasounds were performed starting on day 7/8 [21]. Day of PRP infusion was not given in the initial study.…”

Section: Methodsmentioning

confidence: 99%

“…Both Zadehmodarres and Nazari and their colleagues drew 17.5 ml of blood on day 9 or 10 of HRT into 2.5 ml of ACD-A and similarly centrifuged twice to obtain 0.5 ml of PRP [19,20]. Tandulwadkar et al used 10 ml of autologous blood into an unspecified amount of ACD-A; which was centrifuged sequentially utilizing first a soft spin for 15 minutes, followed by a hard spin for 6 minutes, again yielding between 0.5 and 0.8 ml of PRP [21]. Eftekhar and others used an alternative approach, collecting PRP on the 13th day of HRT by drawing 8.5 ml of peripheral venous blood into a syringe containing 1.5 ml of ACD-A that was then centrifuged for 10 minutes; following first centrifugation, the buffy coat and plasma layer were then removed and centrifuged again, yielding 1.5 ml of PRP [22].…”

Section: Prp Collection and Infusionmentioning

confidence: 99%

“…Chang et al performed a secondary study as well, involving a larger cohort of patients compared against a control group, and performed PRP collection as previously reported [18,25]. All studies transfused the PRP into the endometrium using an IUI catheter, and then repeated intravaginal ultrasound 48 hours later to measure endometrial growth; patients who did not reach the desired lining thickness (>7 mm deemed adequate in all studies) were then treated with a second round of PRP infusion [18][19][20][21][22][23][24][25].…”

Section: Prp Collection and Infusionmentioning

confidence: 99%

“…Of 346 patients, 313 underwent embryo transfer at either cleavage or blastocyst stage. The remaining 33 patients dropped out of the studies prior to embryo transfer due to persistently poor endometrial development [18][19][20][21][22][23][24][25].…”

Section: Sample Size and Selection Of Samplesmentioning

confidence: 99%

See 4 more Smart Citations

Autologous Platelet-Rich Plasma Infusion to Improve Pregnancy Outcome in Suboptimal Endometrium: A Review

Zeffiro¹,

Bocca²,

Russell³

et al. 2020

Innovations in Assisted Reproduction Technology

View full text Add to dashboard Cite

Over the past decade, platelet-rich plasma (PRP) has been used in several fields of medicine to promote cell growth and expedite wound healing for the treatment of arthritis, nerve injury, tendinitis, bone regeneration, cardiac muscle repair, and oral & plastic surgery. Recently, researchers have been applying autologous PRP to bolster the growth of endometrial lining in patients with a history of endometriumrelated failed embryo transfers. Evidence reveals that PRP is a rich source of active cytokines and various growth factors, which come from an autologous source that can be easily attained from peripheral blood without risk of disease transmission to the patient. In this review, several studies were analyzed that involved patients 18-42 years of age undergoing hormone replacement therapy (HRT) in preparation for embryo transfer and serial transvaginal ultrasound in conjunction with PRP infusions into the endometrium via an intrauterine insemination (IUI) catheter. Exclusion criteria included patients with endometritis, polyps, or adhesions. Embryo transfers (ET) were performed when the endometrial lining achieved a thickness of >7 mm. The database indicates that PRP infusion therapy is a promising low-cost treatment for HRT patients that significantly increases endometrial thickness and improves pregnancy success in a previous suboptimal ET patient population.Evidence shows that PRP infusion directly into the endometrium enhances lining development in patients suffering from chronically refractive or underdeveloped endometrium. Chemical pregnancy in patients that underwent PRP infusion with frozen embryo transfer was 50% (108/216) in comparison to 17.1% (16/93) in patients that did not receive PRP treatment. Innovations in Assisted Reproduction Technology 2Autologous

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Prp Collection and Infusionmentioning

confidence: 99%

Section: Prp Collection and Infusionmentioning

confidence: 99%

Section: Sample Size and Selection Of Samplesmentioning

confidence: 99%

See 3 more Smart Citations

Autologous Platelet-Rich Plasma Infusion to Improve Pregnancy Outcome in Suboptimal Endometrium: A Review

Zeffiro¹,

Bocca²,

Russell³

et al. 2020

Innovations in Assisted Reproduction Technology

View full text Add to dashboard Cite

show abstract

Investigation of platelet‐rich plasma in increasing proliferation and migration of endometrial mesenchymal stem cells and improving pregnancy outcome of patients with thin endometrium

Wang

Liu

Mou

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Background Platelet‐rich plasma (PRP) contains abundant growth factors and is gradually used in the field of reproduction. A thin endometrium is recognized as a critical factor in embryo implantation failure. Endometrial mesenchymal stem cells (EnMSCs), which were isolated from human menstrual blood, are highly proliferative and show multiple differentiation capacity. The current study was to investigate the effect of PRP on the proliferation and migration of EnMSCs, and the effectiveness of PRP in the treatment of patients with thin endometrium. Materials and Methods EnMSCs were treated with PRP in vitro, followed by measuring cell proliferation, migration, and adhesion by using CCK8, scratch, and adhesion test, respectively. Twenty patients undergoing in vitro fertilization (IVF) with refractory thin endometrium history were given PRP by infusion into the uterine cavity after the treatment of hormone replacement therapy (HRT). Results All components of PRP significantly stimulated the growth, migration, and adhesion of EnMSCs when compared with the negative control. Cell proliferation and migration were induced by PRP in a dose‐dependent manner with maximum proliferation at a 2% PRP dose. The clinical data showed that successful endometrial expansion and pregnancy were discovered in 12 patients after PRP infusion, and the pregnancy rate increased to 60%. Conclusion Intrauterine PRP infusion represents a new way for female patients with thin endometrium with poor response. This study lays the foundations for the potential treatment of thin endometrium with PRP in vivo.

show abstract

Strategies for managing Asherman's syndrome and endometrial atrophy: Since the classical experimental models to the new bioengineering approach

Miguel-Gómez

Romeu

Pellicer

et al. 2021

Molecular Reproduction Devel

View full text Add to dashboard Cite

Endometrial function is essential for embryo implantation and pregnancy, but managing endometrial thickness that is too thin to support pregnancy or an endometrium of compromised functionality due to intrauterine adhesions is an ongoing challenge in reproductive medicine. Here, we review current and emerging therapeutic and experimental options for endometrial regeneration with a focus on animal models used to study solutions for Asherman's syndrome and endometrial atrophy, which both involve a damaged endometrium. A review of existing literature was performed that confirmed the lack of consensus on endometrial therapeutic options, though promising new alternatives have emerged in recent years (platelet-rich plasma, exosomes derived from stem cells, bioengineering-based techniques, endometrial organoids, among others). In the future, basic research using established experimental models of endometrial pathologies (combined with new high-tech solutions) and human clinical trials with large population sizes are needed to evaluate these emerging and new endometrial therapies.

show abstract

Autologous intrauterine platelet-rich plasma instillation for suboptimal endometrium in frozen embryo transfer cycles: A pilot study

Cited by 74 publications

References 14 publications

Autologous Platelet-Rich Plasma Infusion to Improve Pregnancy Outcome in Suboptimal Endometrium: A Review

Autologous Platelet-Rich Plasma Infusion to Improve Pregnancy Outcome in Suboptimal Endometrium: A Review

Investigation of platelet‐rich plasma in increasing proliferation and migration of endometrial mesenchymal stem cells and improving pregnancy outcome of patients with thin endometrium

Strategies for managing Asherman's syndrome and endometrial atrophy: Since the classical experimental models to the new bioengineering approach

Contact Info

Product

Resources

About